Dublin Steroid Cancer Meeting is a two-day unique meeting that aims to bring together world leaders in an intimate setting that will foster critical idea exchange, inspiration and collaboration. This year’s conference theme will focus on epigenetic and metabolic dysregulation in cancer, emerging immunotherapies and the influence of the tumour microenvironment, with talks on basic research and translational implications.

The conference chairs are currently developing their detailed programme, which will include the complete meeting schedule, as well as the talk titles for all invited speakers and short talks selected from abstract submissions. Please check back for updates.

Dublin Steroid Cancer Conference 2018

Chairs: Leonie Young, RCSI, Donald P McDonnell, Duke University, Damir Varešlija, RCSI


Monday 15thOctober

08.00 –08:50      Registration,The Front Hall,RCSI, 123 St Stephen’s Green

08:50 – 9:00        Introductory Comments by the Conference Chair

Session 1: Genomic Approaches to Understanding Steroid Dependent Cancer

9:00-9:30 Adrian Lee, University of Pittsburgh (USA)

The Genomics of Breast Cancer Metastasis

9:30-10:00 Leonie Young, Royal College of Surgeons in Ireland (Ireland)

Epigenetic and Transcriptomic Aberrations in Advanced Breast Cancer

10:00-10:30 Rachael Natrajan, The Institute of Cancer Research (UK)

Alternative Splicing as a Driver of ER+ Breast Cancer


Session Chairs: Ray Stallings, RCSI

Tea and coffee, The Front Hall, RCSI               10:30 – 11: 00

Session 2: Epigenetic Mechanisms of Cancer Progression

11:00-11:30 Michael Kharas, Memorial Sloan Kettering Cancer Center (USA)

RNA regulators and epigenetic control of leukemia self-renewal

11:30-12:00 Adrian Bracken, Trinity College Dublin (Ireland)

A novel isoform of Ligand-dependent corepressor (LCOR) essential for Polycomb mediated repression and embryonic development

12:00-12:30 Giovanni Ciriello, University of Lausanne (Switzerland)

Cancer epigenetic dependencies in 3D

12:30-13:00 Jana Jeschke,  Free University of Brussels (Belgium)

Detecting changes in the tumor microenvironment through epigenetic profiling

Session Chairs: Darran O’Connor

Lunch and Poster viewing, The Exam Hall, RCSI             13.00 – 14.00

Session 3: Nuclear Receptor I

Session Chairs: Marie McIlroy

14:00-14:30 Geoff Greene, University of Chicago (USA)

Novel Approaches to Exploiting Steroid Receptors in Breast Cancer

14:30-15:00 Myles Brown, Dana Farber Cancer Institute (USA)

Essential Cistromes Driving Hormone-Dependent Cancers

15:00-15:30 Wayne Tilley, University of Adelaide (Australia)

Targeting the androgen receptor in estrogen receptor-α positive breast cancer

15:30-16:00 Charlotte Bevan, Imperial College London (UK)

MicroRNAs, androgen receptor and therapy resistance in prostate cancer

Tea and coffee, The Front Hall, RCSI             16:00 – 16: 30

Session 4 –SFI Keynote Speaker  

Introduction: Donald P McDonnell

16:30 – 17:30     Bert O’Malley, Baylor College of Medicine (USA)

Can Coactivator Molecular Biology Substantiate Sugar as the ‘White Death’?                                                              


Tuesday 16th  October

Session 5: Tumour Resistance Mechanisms

Session Chairs: Jochen Prehn and Arnold Hill

10:00-10:30 Steffi Oesterreich, University of Pittsburgh (USA)

Mutant ER – Above and Beyond Endocrine Resistance

10:30-11:00 James Valerinano Alvarez, Duke University (USA)

Clonal dynamics during residual disease and recurrence

11:00-11:15 Suzan Stelloo,  NKI, (Netherlands)

Integrative epigenetic taxonomy of primary prostate cancer

11:15-11:30 Claire Fletcher,  Imperial College London (UK)

Mir-346 Interaction With Long Non-Coding Rna, Norad, Reveals A Novel Genome Protection Mechanism And Modulates Response To DNA-Damaging Therapeutics In Advanced Prostate Cancer

Tea and coffee, The Front Hall, RCSI               11:30 – 12: 00

Session 6: Nuclear Receptors II

Session Chairs: Liam Gallagher

12:00-12:30 Wilbert Zwart, NKI, Netherlands

From cistromics to novel therapeutics in hormone dependent cancers

12:30-13:00 Donald McDonnell, Duke University (USA)

Cancer cell selective inhibition of mitochondrial function as a therapeutic approach in breast cancer

13:00-13.30 Scott Dehm, University of Minnesota (USA)

Role and Origin of Androgen Receptor Variants in Prostate Cancer

Lunch and Poster viewing, The Exam Hall, RCSI            13.30 – 14.30

Session 7: Model Systems and Novel Therapeutics

Session Chairs: Ann Hopkins

14:30-15:00 Cathrin Brisken,  Ecole Polytechnique Federale de Lausanne (Switzerland)

Humanizing mouse mammary glands to study hormone-dependent breast carcinogenesis

15:00-15:30 Karen Knudsen, Sidney Kimmel Cancer Center (USA)

Targeting AR-DNA Repair Crosstalk in Aggressive Prostate Cancer

15:30-15:45 Sara Charmsaz, RCSI (Ireland)

Therapeutic Targets and Companion Diagnostics in Endocrine Resistant Breast Cancer

15:45-16:00 Colm Ryan, UCD (Ireland)

The regulation of protein complexes in breast cancer

Tea and coffee, The Front Hall, RCSI             16:00 – 16: 30


16:30-17:00 Triona Ni Chonghaile , RCSI (Ireland)

Discovery of a novel specific HDAC6 inhibitor

17:00-17:30 Tracy Robson, RCSI (Ireland)

Harnessing the Anti-angiogenic and Anti-cancer Stem Cell Properties of FKBPL; Discovery to Clinic


Closing Remarks and General Discussion